CRISPR: the gene editing tool making the world go round – Lexology
Life Sciences Intellectual Property Review |
CRISPR: the gene editing tool making the world go round
Lexology The battle over clustered regularly interspaced short palindromic repeat (CRISPR) technology between Feng Zhang and the Broad Institute at the Massachusetts Institute of Technology on the one side and Jennifer Doudna, Emmanuelle Charpentier, Krzysztof … Mixed views on Broad’s fate after EPO revokes CRISPR patentLife Sciences Intellectual Property Review |
Pacific Standard |
Why Gene Therapy Is No Longer a Pipe Dream
Pacific Standard Last year will be remembered for many things, many of them not good. But here’s at least one flicker of hope: 2017 may go down as the year gene therapy finally turned a corner. In late December, the Food and Drug Administration announced its approval … FDA Approves Spark Therapeutics’ Gene Therapy for Inherited Vision LossTheafricom |
|
uniQure Aims to Begin First Human Trial of Investigational Gene Therapy AMT-130 for Huntington’s in 2018
Huntington’s Disease News uniQure expects to advance the clinical development of its Huntington’s disease investigational gene therapy, called AMT-130, during 2018. The company says it plans to file an investigational new drug application (IND) with the U.S. Food and Drug … |
Technology Networks |
Possible Biomarker to Identify Who Would Benefit from Immunotherapy
Technology Networks While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. “This begs the question: Why does it work in those patients? We don’t understand the mechanism at work … |
|
Welcome to London! Meet RebelBio’s Fifth Cohort of Biotech Startups
Labiotech.eu (blog) Irish accelerator RebelBio has launched its latest cohort of startups that will receive its support during a 3-month program at Imperial College London. RebelBio is a startup accelerator that helps entrepreneurs to build technology associated with the … |
Labiotech.eu (blog) |
France Gets Ready to Test CAR-Treg Cells to Avoid Transplant Rejection
Labiotech.eu (blog) French biotech TxCell is finalizing the preparations to take its first cell therapy to clinical trials. The treatment, called HLA-A2 CAR-Treg, is intended for the prevention of chronic rejection after organ transplantation. Out of the €5M needed to … Government funds TxCell’s CAR-Treg therapyEuropean Biotechnology |